Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rovadicitinib in Ruxolitinib-Refractory/Intolerant Myelofibrosis
NCT06388759Phase 1Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rovadicitinib in myelofibrosis (MF), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Spleen Volume Reduction >= 35% at 24 weeks. Started Aug 2022; status: terminated.
02
Drugs
rovadicitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06388759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388759.